| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 01/23/2003 | WO2002088143A3 Dihydroimidazo[4,5-e]indole and 7h-pyrrolo[3,2-f]quinoxaline derivatives as nicotinic acetylcholine receptor ligands and/or serotonergic ligands |
| 01/23/2003 | WO2002083159B1 Palliative effects of morinda citrifolia oil and juice |
| 01/23/2003 | WO2002072094A3 Use of neuroactive substances and combinations thereof for the treatment of parkinsons disease |
| 01/23/2003 | WO2002060436A3 Use of fredericamycin a and its derivatives in the treatment of pin1-associated states |
| 01/23/2003 | WO2002056790A3 Delivery of therapeutic capable agents |
| 01/23/2003 | WO2002055152A9 Composition for inducing islet neogenesis, containing gastrin/cck receptor ligands and egf receptor ligands |
| 01/23/2003 | WO2002053711A3 Use of transcription factor yb-1 in adenoviral systems |
| 01/23/2003 | WO2002051808A3 Muscarinic antagonists |
| 01/23/2003 | WO2002050066A3 Pyrazole compounds useful as protein kinase inhibitors |
| 01/23/2003 | WO2002049413A3 Thrombopoietin mimetics |
| 01/23/2003 | WO2002046171A3 Anilinopyrimidine derivatives as ikk inhibitors and compositions and methods related thereto |
| 01/23/2003 | WO2002041835A3 Estrogen receptor modulators |
| 01/23/2003 | WO2002036767A3 Therapeutic oligonucleotides of reduced toxicity |
| 01/23/2003 | WO2002036741A3 Polynucleotide encoding an activated human t-lymphocyte-derived protein related to ubiquitin conjugating enzyme |
| 01/23/2003 | WO2002036562A3 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands |
| 01/23/2003 | WO2002033095A3 Regulation of human serine-threonine protein kinase |
| 01/23/2003 | WO2002020773A3 Chimeric antisense oligonucleotides of arabinofuranose analogues and deoxyribose nucleotides |
| 01/23/2003 | WO2002020619A3 HUMAN ANTIBODIES AGAINST PSEUDOMONAS AERUGINOSA LPS DERIVED FROM TRANSGENIC XENOMOUSE$m(3) |
| 01/23/2003 | WO2002020569A3 Mammalian genes; related reagents and methods |
| 01/23/2003 | WO2002019998A3 A method of treating weight gain associated with atypical antipsychotic use |
| 01/23/2003 | WO2002016553A3 Regulator gene and system useful for the diagnosis and therapy of osteoporosis |
| 01/23/2003 | WO2002013798A3 Treatment of the insulin resistance syndrome with selective cgmp pde5 inhibitors |
| 01/23/2003 | WO2002010405A3 A human disintegrin protein |
| 01/23/2003 | WO2002010363A3 Protein phosphatases |
| 01/23/2003 | WO2002009760A3 Epoxy-steroidal aldosterone antagonist and beta-adrenergic antagonist combination therapy for treatment of congestive heart failure |
| 01/23/2003 | WO2002002607A3 Acid-modified arabinogalactan protein composition |
| 01/23/2003 | WO2001097843A3 Methods for enhancing antibody-induced cell lysis and treating cancer |
| 01/23/2003 | WO2001083782A3 Novel proteases |
| 01/23/2003 | US20030018987 Animal model for use in the diagnosis and treatment of eating, apoptosis and infectious disorders |
| 01/23/2003 | US20030018199 Process for preparing chiral diol sulfones and dihydroxy acid HMG CoA reductase inhibitors |
| 01/23/2003 | US20030018193 Beta-alanine derivatives and their use as receptor anatgonists |
| 01/23/2003 | US20030018083 Methods of treating and preventing pain, anxiety, and incontinence using derivatives of (-)-venlafaxine |
| 01/23/2003 | US20030018079 Treatment |
| 01/23/2003 | US20030018077 Compounds which interact with the thyroid hormone receptor for the treatment of fibrotic disease |
| 01/23/2003 | US20030018074 Antiinflammatory agents; skin disorders; topical applying |
| 01/23/2003 | US20030018067 Cardiovascular disorders; anticancer agents |
| 01/23/2003 | US20030018066 Administering vitamin e and selenium, or compound thereof |
| 01/23/2003 | US20030018061 Novel remedies with the use of beta 3 agonist |
| 01/23/2003 | US20030018058 3-aminopyrazole inhibitors of cyclin dependent kinases |
| 01/23/2003 | US20030018053 Substituted indolealkanoic acids |
| 01/23/2003 | US20030018049 Azithromycin combination for emesis control in mammals |
| 01/23/2003 | US20030018046 Chemokine receptor binding heterocyclic compounds |
| 01/23/2003 | US20030018041 Spiroindene and spiroindane compounds |
| 01/23/2003 | US20030018040 Tumor necrosis factor antagonist; side effect reduction;antiinflammatory agents |
| 01/23/2003 | US20030018038 1,4 substituted piperidinyl NMDA/NR2B antagonists |
| 01/23/2003 | US20030018035 Central nervous system disorders |
| 01/23/2003 | US20030018026 Preterm labor; urogenital disorders; fertility; psychological disorders |
| 01/23/2003 | US20030018021 Piperidine derivatives as subtype selective N-methyl-D-aspartate antagonists |
| 01/23/2003 | US20030018016 Cell adhesion inhibitors |
| 01/23/2003 | US20030018008 Synergistic mixture of adenosine antagonist and antiserotonine agent |
| 01/23/2003 | US20030017992 Crystalline forms |
| 01/23/2003 | US20030017991 Substrates and assays for beta-secretase activity |
| 01/23/2003 | US20030017988 Compositions for treating abnormalities in glomerular filtration, patent ductus arteriosus and osteoporosis |
| 01/23/2003 | US20030017977 Methods of treating inflammatory skin diseases |
| 01/23/2003 | US20030017975 Immunosuppressants; activation of lipopeptide fungicides |
| 01/23/2003 | US20030017969 Methods and pharmaceutical compositions for healing wounds |
| 01/23/2003 | US20030017965 Methods for treating certain diseases using naaladase inhibitors |
| 01/23/2003 | US20030017617 Mammalian receptor proteins; related reagents and methods |
| 01/23/2003 | US20030017589 Culturing preferential cells; generate nutrient broth, inoculate with cells, propagate cells, recover cells |
| 01/23/2003 | US20030017562 Nucleotide sequences coding polypetide for use in the treatment, prevention and diagnosis of gastrointestinal and apoptosis disorders |
| 01/23/2003 | US20030017548 Proteins for use in treatment of gastrointestinal disorders |
| 01/23/2003 | US20030017533 Slo2 and Slo4, novel potassium channel proteins from human brain |
| 01/23/2003 | US20030017532 ndp |
| 01/23/2003 | US20030017527 Human vanilloid receptor-like proteins |
| 01/23/2003 | US20030017520 High-efficiency assay for protein mannosyl transferases |
| 01/23/2003 | US20030017512 Angiostatin receptor |
| 01/23/2003 | US20030017479 Methods for the detection, treatment, and prevention of neurodegeneration |
| 01/23/2003 | US20030017468 Nucleotide sequences which code lung preferential gene for use in the treatment and diagnosis of lung cancer |
| 01/23/2003 | US20030017218 Soft tissue anticancer agents |
| 01/23/2003 | US20030017217 Extraction, purification and solvent evaporation of leaves that have been dried at </= 35 degrees C; reinforcing cellular immunity and delayed hypersensitivity in healthy humans, activating and proliferating t-lymphocytes |
| 01/23/2003 | US20030017215 Soft tissue anticancer agents |
| 01/23/2003 | US20030017164 Dye-azide compounds for dual phototherapy |
| 01/23/2003 | US20030017161 Polypeptides that are capable of modulating apoptosis; also Apo-2 chimeras, nucleic acid encoding Apo-2, and antibodies to Apo-2 |
| 01/23/2003 | US20030017155 Treating a condition characterized by activation of the inflammatory cytokine cascade |
| 01/23/2003 | US20030017153 Determining whether a patient's immune system can be modified through stimulation of thymus function; sex steroids are ablated in the patient, and the resulting production of thymic factors is monitored. |
| 01/23/2003 | US20030017151 Receptor Activator of NF-kappa B antagonists; treatment of medical conditions that require the formation of new bone. |
| 01/23/2003 | US20030017141 Treatment of conditions characterized by a need to modulate migratory-cell movement associated with specific sites in a subject; isolating a stromal-cell-derived fugetactic agent |
| 01/23/2003 | US20030017120 Delivery of erectile dysfunction drugs through an inhalation route |
| 01/23/2003 | US20030017119 Aerosol comprises particles comprising at least 10 percent by weight of an opioid, and wherein the opioid is not heroin; opiods include morphine, codeine, naltrexone, buprenorphine, fentanyl, nalbuphine, naloxone, etc. |
| 01/23/2003 | US20030017118 An aerosol for inhalation therapy, wherein the aerosol comprises particles comprising at least 10 percent by weight of an antipsychotic such as olanzapine, trifluoperazine, haloperidol, loxapine, clozapine, quetiapine, promazine, etc. |
| 01/23/2003 | US20030017117 Delivery of analgesics through an inhalation route |
| 01/23/2003 | US20030017116 Delivery of sedative-hypnotics through an inhalation route |
| 01/23/2003 | US20030017115 Aerosol comprises particles comprising at least 10 percent by weight of a drug ester. |
| 01/23/2003 | US20030017114 Aerosol comprises particles of chlordiazepoxide, betahistine, clonidine, testosterone, conjugated estrogens, estrogen esters, estradiol, estradiol esters, ethinyl estradiol, ethinyl estradiol esters, or hyoscyamine. |
| 01/23/2003 | US20030015190 Delivery of compounds for the treatment of migraine through an inhalation route |
| 01/23/2003 | US20030015189 Delivery of antihistamines through an inhalation route |
| 01/23/2003 | CA2821544A1 Use of follistatin for the treatment of pulmonary fibrosis and fibrosis associated with inflammatory bowel disease |
| 01/23/2003 | CA2707767A1 Biologically active peptides |
| 01/23/2003 | CA2454135A1 Gpcs as modifiers of the irrtk and p21 pathways and methods of use |
| 01/23/2003 | CA2453566A1 Method and composition for inhibiting heparanase activity |
| 01/23/2003 | CA2453554A1 Heteroaryl substituted fused bicyclic heteroaryl compounds as gabaa receptor ligands |
| 01/23/2003 | CA2453503A1 N-(3-amino-2-hydroxy-propyl) substituted alkylamide compounds |
| 01/23/2003 | CA2453470A1 Use of follistatin for the treatment of hepatic fibrogenesis |
| 01/23/2003 | CA2453447A1 Alpha-hydroxyamide statine derivatives for the treatment of alzheimer's disease |
| 01/23/2003 | CA2453444A1 Diaminediols for the treatment of alzheimer's disease |
| 01/23/2003 | CA2453403A1 Methods of inhibiting amyloid toxicity |
| 01/23/2003 | CA2453399A1 Combinations for the treatment of inflammatory disorders |
| 01/23/2003 | CA2453346A1 A hydroxamic acid thrombospondin peptide analog that inhibits aggrecanase activity |
| 01/23/2003 | CA2453187A1 Production of transduced hematopoietic progenitor cells |
| 01/23/2003 | CA2453182A1 Crystalline thiazine oxazolidinones |